PHARMACEUTICAL PRODUCT DEVELOPMENT INC Costs and Expenses
PHARMACEUTICAL PRODUCT DEVELOPMENT INC reported Costs and Expenses of $349.98 million for the 3-month period ending 2011-09-30, per its 10-Q filed 2011-11-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2011-11-02
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC costs and expenses for the quarter ending 2011-09-30 was $349.98M, a 13.43% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC costs and expenses for the quarter ending 2011-06-30 was $350.56M, a 6.28% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC costs and expenses for the quarter ending 2011-03-31 was $330.75M, a 3.66% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC costs and expenses for the quarter ending 2010-12-31 was $325.66M, a 1.90% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC costs and expenses for fiscal 2010 was $1.28B, a 6.71% increase from fiscal 2009.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC costs and expenses for fiscal 2009 was $1.20B, a 5.24% decline from fiscal 2008.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC costs and expenses for fiscal 2008 was $1.27B.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2011-09-30 | $349.98M 10-Q · filed 2011-11-02 | $700.53M derived: sum of 2 quarters · filed 2011-11-02 | $1.03B 10-Q · filed 2011-11-02 | $1.36B derived: sum of 4 quarters · filed 2011-11-02 |
| 2011-06-30 | $350.56M 10-Q · filed 2011-08-04 | $681.31M 10-Q · filed 2011-08-04 | $1.01B derived: sum of 3 quarters · filed 2011-08-04 | $1.32B derived: sum of 4 quarters · filed 2011-11-02 |
| 2011-03-31 | $330.75M 10-Q · filed 2011-05-03 | $656.41M derived: sum of 2 quarters · filed 2011-05-03 | $964.95M derived: sum of 3 quarters · filed 2011-11-02 | $1.29B derived: sum of 4 quarters · filed 2011-11-02 |
| 2010-12-31 | $325.66M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $634.20M derived: sum of 2 quarters · filed 2011-11-02 | $964.03M derived: sum of 3 quarters · filed 2011-11-02 | $1.28B 10-K · filed 2011-02-25 |
| 2010-09-30 | $308.54M 10-Q · filed 2011-11-02 | $638.38M derived: sum of 2 quarters · filed 2011-11-02 | $957.46M 10-Q · filed 2011-11-02 | $1.28B derived: sum of 4 quarters · filed 2011-11-02 |
| 2010-06-30 | $329.83M 10-Q · filed 2011-08-04 | $648.92M 10-Q · filed 2011-08-04 | $968.50M derived: sum of 3 quarters · filed 2011-08-04 | $1.26B derived: sum of 4 quarters · filed 2011-08-04 |
| 2010-03-31 | $319.09M 10-Q · filed 2011-05-03 | $638.66M derived: sum of 2 quarters · filed 2011-05-03 | $927.44M derived: sum of 3 quarters · filed 2011-05-03 | $1.22B derived: sum of 4 quarters · filed 2011-05-03 |
| 2009-12-31 | $319.58M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $608.35M derived: sum of 2 quarters · filed 2011-02-25 | $904.68M derived: sum of 3 quarters · filed 2011-02-25 | $1.20B 10-K · filed 2011-02-25 |
| 2009-09-30 | $288.77M 10-Q · filed 2010-11-05 | $585.11M derived: sum of 2 quarters · filed 2010-11-05 | $882.89M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $296.33M 10-Q · filed 2010-08-06 | $594.12M 10-Q · filed 2010-08-06 | ||
| 2008-12-31 | $1.27B 10-K · filed 2011-02-25 |